source
- Marea Therapeutics reports promising Phase 2b results for MAR001 in hypertriglyceridemiaMarea Therapeutics, which recently merged with oncology firm Lisata Therapeutics, disclosed data from the first part of its phase 2b trial of the drug candidate MAR001. The study enrolled patients…
- Boehringer targets 2027 submission of obesity drug survodutide after positive cardiovascular trialBoehringer Ingelheim announced that its experimental obesity therapy survodutide is moving toward regulatory filing. The move follows the drug's successful phase 3 cardiovascular outcomes study, w…Fierce Biotech · 3d agoPositive readoutPositive